Liposome Co. reaches milestone
The Liposome Co. and Schering AGhave reached a milestone in their development of TLC I-16, a liposomalnonionic contrast agent for CT scans of the liver. The firms haveagreed on the formulation of the prototype product and will nowproceed from research to
The Liposome Co. and Schering AGhave reached a milestone in their development of TLC I-16, a liposomalnonionic contrast agent for CT scans of the liver. The firms haveagreed on the formulation of the prototype product and will nowproceed from research to a product development program.
The companies will jointly conduct preclinical testing of TLCI-16, with the Liposome Co. responsible for formulation developmentand Schering conducting preclinical studies in animals. Scheringwill provide developmental funding.
TLC I-16 is an imaging agent that is encapsulated within liposomes,using a proprietary process. The product is being developed foruse with CT scans of patients with advanced colon, lung or breastcancer in whom there is suspicion that cancer has metastasizedto the liver.
On regulatory approval of TLC I-16, the Liposome Co. will manufacturethe agent and Schering will market it globally.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
